Drug Approval | November 04, 2022
Alembic receives USFDA approval for Ketorolac Tromethamine Injection
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
Ketorolac Tromethamine is advised for the short-term management of moderately severe acute pain in adult patients
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Innovative Capsugel Enprotect capsule can simplify the manufacturing process to accelerate drug development and expedite first-in-human timelines
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Menon has over 41 years of diverse experience in some of the premier multinational and Indian companies in the chemical and power industry
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Subscribe To Our Newsletter & Stay Updated
